Alaunos Narrows Losses, Boosts Cash Amid Nasdaq Delisting Threat

TL;DR

**TCRT is a high-risk bet, as they're burning cash and facing delisting, despite a recent capital injection.**

AI Summary

Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $1.051 million for the three months ended June 30, 2025, a slight improvement from the $1.129 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $2.124 million, compared to $2.810 million in 2024. Revenue remained negligible, at $0 for the quarter and $2,000 for the six months ended June 30, 2025. The company significantly increased its cash and cash equivalents to $2.879 million as of June 30, 2025, up from $1.091 million at December 31, 2024, primarily due to $3.261 million in financing activities, including the issuance of common stock, prefunded warrants, and Series A-1 and A-2 preferred stock. Operating expenses decreased, with general and administrative expenses falling to $854,000 for the quarter from $990,000 in 2024, and to $1.603 million for the six months from $2.607 million in 2024. Research and development expenses saw a modest increase to $185,000 for the quarter and $531,000 for the six months ended June 30, 2025. The company's total stockholders' equity increased to $3.661 million from $2.063 million at December 31, 2024, but it still faces a Nasdaq delisting notice due to shareholder equity falling below $2.5 million.

Why It Matters

This filing reveals Alaunos Therapeutics is in a critical financial and strategic juncture. While the company has improved its cash position to $2.879 million and reduced its net loss, the ongoing Nasdaq delisting notice due to shareholder equity below $2.5 million poses a significant threat to its market viability and ability to raise future capital. For investors, this signals high risk and potential for further dilution if the company needs to issue more equity to meet listing requirements or fund its early-stage obesity program. Employees face uncertainty regarding the company's long-term stability, especially given the mention of potential dissolution and liquidation if strategic transactions fail. Competitively, the company's early-stage obesity program and paused TCR-T candidates mean it lags behind more established biotech firms, making its ability to secure partnerships or achieve commercialization challenging.

Risk Assessment

Risk Level: high — The company explicitly states it 'may require substantial additional financial resources to continue as a going concern' and has received a Nasdaq delisting notice because its shareholder equity fell below $2.5 million, specifically to $2.063 million at December 31, 2024. Furthermore, the filing mentions the Board of Directors may pursue 'dissolution and liquidation' if a strategic transaction is not consummated, indicating severe financial distress.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor the company's progress on its Nasdaq compliance plan and any strategic transaction announcements closely. Given the 'going concern' warning and potential for dissolution, new investments carry substantial risk.

Financial Highlights

debt To Equity

0.28

revenue

$0

operating Margin

-100.0%

total Assets

$4,735,000

total Debt

$1,074,000

net Income

-$1,051,000

eps

-$0.63

gross Margin

N/A

cash Position

$2,879,000

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $2.879M — Cash and Cash Equivalents (Increased from $1.091M at Dec 31, 2024, due to financing activities.)
• $2.124M — Net Loss (Six Months) (Improved from $2.810M in the prior year period.)
• $3.661M — Total Stockholders' Equity (Increased from $2.063M at Dec 31, 2024, but still below Nasdaq's $2.5M minimum at year-end 2024.)
• $3.261M — Net Cash from Financing (Primary source of cash increase, including stock and preferred stock sales.)
• $0 — Revenue (Q2 2025) (Remains negligible, indicating no commercial products.)
• $1.603M — General & Administrative Expenses (Six Months) (Decreased from $2.607M in the prior year period.)
• $531K — Research & Development Expenses (Six Months) (Increased from $306K in the prior year period, reflecting ongoing preclinical work.)
• 2,194,941 — Outstanding Common Shares (As of August 14, 2025, indicating potential dilution from recent offerings.)

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — registrant of the 10-Q filing
• Nasdaq Capital Stock Market (regulator) — exchange where TCRT is listed and facing delisting
• $2.879 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $1.091 million (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $2.124 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $2.810 million (dollar_amount) — net loss for the six months ended June 30, 2024
• $3.261 million (dollar_amount) — net cash flows from financing activities for the six months ended June 30, 2025
• $3.661 million (dollar_amount) — total stockholders' equity as of June 30, 2025
• $2.063 million (dollar_amount) — total stockholders' equity as of December 31, 2024
• $2,500,000 (dollar_amount) — Nasdaq Listing Rule 5550(b)(1) minimum shareholder equity requirement

FAQ

Risk Factors

• Nasdaq Delisting Risk [high — financial]: The company received a Nasdaq delisting notice because its total stockholders' equity fell below the $2.5 million minimum requirement. While equity increased to $3.661 million as of June 30, 2025, from $2.063 million at December 31, 2024, continued non-compliance poses a significant risk to market accessibility.
• Dependence on Financing [high — financial]: The company's cash position significantly improved to $2.879 million from $1.091 million due to $3.261 million in financing activities, primarily from issuing common stock and preferred stock. This highlights a continued reliance on external funding for operations, which may not be sustainable.
• Limited Operating Revenue [medium — operational]: Revenue for the three months ended June 30, 2025, was $0, and $2,000 for the six months ended June 30, 2025. This lack of commercial revenue indicates the company is still in a pre-commercialization phase, with no current income-generating products.
• Burn Rate and Cash Runway [medium — operational]: Despite a reduction in net loss to $1.051 million for Q2 2025 and $2.124 million for the six months, the company continues to incur significant operating expenses. The current cash balance of $2.879 million needs to be carefully managed against ongoing expenses to ensure sufficient runway.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: As a biotechnology company, Alaunos Therapeutics is subject to extensive regulatory review and approval processes for its therapeutic candidates. Delays or failures in clinical trials or regulatory submissions could significantly impact the company's future prospects.

Industry Context

Alaunos Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel immunotherapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes and securing substantial funding to advance drug candidates through development and potential commercialization.

Regulatory Implications

The company faces significant regulatory risks inherent in drug development, including the need for successful clinical trials and FDA approval. Furthermore, its non-compliance with Nasdaq's minimum equity requirement has led to a delisting notice, posing an immediate regulatory challenge that could impact its ability to raise capital and its stock's liquidity.

What Investors Should Do

1. Monitor Nasdaq compliance status closely.
2. Evaluate the sustainability of the current cash burn rate.
3. Assess the progress and potential of the R&D pipeline.
4. Consider the impact of recent financing activities on potential dilution.

Key Dates

• 2025-06-30: Quarter End — Reported $2.879M cash, $3.661M equity, and a net loss of $1.051M for Q2 2025. Received Nasdaq delisting notice.
• 2024-12-31: Year End — Reported $1.091M cash and $2.063M equity.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents the cumulative losses that have not been offset by profits. (Indicates the company has historically operated at a loss, with a deficit of $922,570 thousand as of June 30, 2025.)

Additional paid-in capital

The amount of capital received from investors in exchange for stock that exceeds the par value of the stock. (Represents a significant portion of the company's equity, totaling $926,229 thousand, reflecting past stock issuances.)

Prefunded warrants

A type of warrant that allows the holder to purchase shares at a nominal price, often used in financing rounds to avoid immediate dilution for certain investors. (Mentioned as part of financing activities, contributing to the increase in cash but potentially indicating future dilution.)

Series A-1 and A-2 preferred stock

Specific classes of preferred stock issued by the company, likely with different rights and preferences compared to common stock. (These were issued as part of recent financing, contributing to the increase in cash and equity.)

Year-Over-Year Comparison

Compared to the prior year period, Alaunos Therapeutics has improved its net loss for the six months ended June 30, 2025, to $2.124 million from $2.810 million. Operating expenses have decreased, particularly general and administrative costs, while R&D expenses saw a modest increase. Revenue remains negligible. The company has significantly boosted its cash reserves through financing activities, leading to an increase in total stockholders' equity, though it still faces a Nasdaq delisting notice.

Key Financial Figures

• $0.001 — hares of the registrant's common stock, $0.001 par value, was 2,194,941 shares. SPEC
• $2,500,000 — in our shareholder equity falling below $2,500,000 as required by Nasdaq Listing Rule 5550

Filing Documents

• tcrt-20250630.htm (10-Q) — 1475KB
• tcrt-ex31_1.htm (EX-31.1) — 14KB
• tcrt-ex32_1.htm (EX-32.1) — 8KB
• 0000950170-25-108887.txt ( ) — 5393KB
• tcrt-20250630.xsd (EX-101.SCH) — 997KB
• tcrt-20250630_htm.xml (XML) — 584KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25 1

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Condensed Financial Statements (unaudited)

Item 1. Condensed Financial Statements (unaudited) Alaunos Therapeutics, Inc. CONDENSED BALANCE SHEETS (in thousands, except share and per share data) June 30, December 31, 2025 2024 ASSETS: Current assets: Cash and cash equivalents $ 2,879 $ 1,091 Receivables 2 5 Prepaid expenses and other current assets, current 857 1,659 Total current assets 3,738 2,755 Prepaid expenses and other assets, non current 997 — Total assets $ 4,735 $ 2,755 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 809 $ 516 Accrued expenses 265 176 Total current liabilities 1,074 692 Total liabilities $ 1,074 $ 692 Commitments and contingencies (Note 5) Stockholders' equity Series A-1 preferred stock $ 0.001 par value; 1,000 shares authorized, 500 and 0 shares issued and outstanding at June 30, 2025 and at December 31, 2024, respectively - - Series A-2 preferred stock $ 0.001 par value; 1,000 shares authorized, 850 and 0 shares issued and outstanding at June 30, 2025 and at December 31, 2024, respectively - - Common stock $ 0.001 par value; 50,000,000 shares authorized, 2,074,746 and 1,601,252 shares issued and outstanding at June 30, 2025 and at December 31, 2024, respectively 2 2 Additional paid-in capital 926,229 922,507 Accumulated deficit ( 922,570 ) ( 920,446 ) Total stockholders' equity 3,661 2,063 Total liabilities and stockholders' equity $ 4,735 $ 2,755 The accompanying notes are an integral part of these condensed financial statements. 2 Alaunos Therapeutics, Inc. CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ — $ 4 $ 2 $ 6 Operating expenses: Research and development 185 180 531 306 General and administrative 854 990

View Full Filing

View this 10-Q filing on SEC EDGAR